Sirolimus News and Research

RSS

Variation in exposure to sunlight may affect sensitivity of individuals to drugs

A study from the Swedish medical university Karolinska Institutet has shown that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons.

9 Mar 2011

OrbusNeich's Sapphire II coronary dilatation catheter is now available in the market

OrbusNeich today announced that the next-generation Sapphire II coronary dilatation catheter is now commercially available, following CE Mark approval.

28 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

U.S. FDA clears QMS Everolimus Immunoassay to prevent rejection in kidney transplants

The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients. The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus, a drug that helps prevent rejection in kidney transplants.

14 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Study: Drug-eluting stents outperform BMS for revascularization of CTOs

A systematic review of medical evidence has determined drug-eluting stents outperform bare metal stents for revascularization of chronic total occlusions.

10 Feb 2011

DAPT shows positive outcomes following treatment with OrbusNeich's Genous Stent

Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents and the accompanying requirement of long-term dual antiplatelet therapy showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention.

11 Jan 2011

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

5 Jan 2011

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Xenogenics acquires Ideal BioStent assets

MultiCell Technologies, Inc. and its majority owned subsidiary, Xenogenics Corporation, are pleased to announce the acquisition of the Ideal™ BioStent assets by Xenogenics Corporation from investment funds managed by Western Technology Investment and Silicon Valley Bank. Xenogenics Corporation also entered into a worldwide exclusive license with Rutgers University for rights to certain intellectual property related to the Ideal™ BioStent.

19 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

OrbusNeich completes enrollment in randomized clinical study of Genous Bio-engineered R stent in China

OrbusNeich today reported the completion of patient enrollment in a randomized clinical study of its Genous Bio-engineered R stent at 11 sites in China.

12 Oct 2010

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

SORT-OUT IV trial compares XIENCE V, CYPHER Stent in major acute coronary events

Investigators reported results of SORT-OUT IV, comparing Cordis Corporation's CYPHER Sirolimus-eluting Coronary Stent and Abbott's XIENCE V Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months.

28 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Use of CYPHER stent in diabetic patients can result in significant cost savings

New analysis presented at the Transcatheter Cardiovascular Therapeutics meeting (TCT 2010) in Washington, DC, indicates that the broad use of CYPHER Sirolimus-eluting coronary stent in patients with diabetes would result in substantial cost savings, as compared to the use of everolimus-eluting stents (EES), paclitaxel-eluting stents (PES), or zotarolimus-eluting stents (ZES).

23 Sep 2010